Combined Pharmacologic Inhibition of MEK-ERK and PI3K/mTOR Signaling in Glioblastoma Models Enhances Therapeutic Antitumor Activity

被引：0
|
作者：
Schreck, Karisa [1 ]
Allen, Amy [1 ]
Wang, Jiawen [1 ]
Pratilas, Christine [1 ]
机构：
[1] Johns Hopkins Sch Med, Baltimore, MD USA
来源：
NEUROLOGY | 2019年 / 92卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P2.6-023
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Combination of PI3K/mTOR Inhibitors: Antitumor Activity and Molecular Correlates
    Mazzoletti, Marco
    Bortolin, Francesca
    Brunelli, Laura
    Pastorelli, Roberta
    Di Giandomenico, Silvana
    Erba, Eugenio
    Ubezio, Paolo
    Broggini, Massimo
    CANCER RESEARCH, 2011, 71 (13) : 4573 - 4584
  • [32] Combined inhibition of MEK and PI3K elicits anti-tumor activity in human cholangiocarcinoma
    Yang, Jennifer
    Elnaggar, Omar
    Mace, Thomas
    Farren, Matthew
    Young, Gregory
    Lee, Patrice
    Keenan, Kaitlin
    Che, Zheng
    Kaufman, Jacob
    Guttridge, Denis
    Carbone, David
    Timmers, Cynthia
    Bekaii-Saab, Tanios
    Lesinski, Gregory
    CANCER RESEARCH, 2015, 75
  • [33] Targeting EGFR and PI3K/mTOR pathways in glioblastoma: innovative therapeutic approaches
    Singh, Gursimran
    Rohit, Pankaj
    Kumar, Pankaj
    Aran, Khadga Raj
    MEDICAL ONCOLOGY, 2025, 42 (04)
  • [34] Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer
    Saini, Kamal S.
    Loi, Sherene
    de Azambuja, Evandro
    Metzger-Filho, Otto
    Saini, Monika Lamba
    Ignatiadis, Michail
    Dancey, Janet E.
    Piccart-Gebhart, Martine J.
    CANCER TREATMENT REVIEWS, 2013, 39 (08) : 935 - 946
  • [35] Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma
    Barzegar Behrooz, Amir
    Talaie, Zahra
    Jusheghani, Fatemeh
    Los, Marek J.
    Klonisch, Thomas
    Ghavami, Saeid
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (03)
  • [36] Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy
    Yothaisong, Supak
    Dokduang, Hasaya
    Techasen, Anchalee
    Namwat, Nisana
    Yongvanit, Puangrat
    Bhudhisawasdi, Vajarabhongsa
    Puapairoj, Anucha
    Riggins, Gregory J.
    Loilome, Watcharin
    TUMOR BIOLOGY, 2013, 34 (06) : 3637 - 3648
  • [37] Mapping topology of PI3K/AKT/mTOR signaling in glioblastoma molecular subgroups
    Joy, Anna
    Ramesh, Archana
    Smirnov, Ivan
    Reiser, Mark
    Mills, Gorden
    Kim, Seungchan
    Feuerstein, Burt
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
  • [38] Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide
    Prasad, Gautam
    Sottero, Theo
    Yang, Xiaodong
    Mueller, Sabine
    James, C. David
    Weiss, William A.
    Polley, Mei-Yin
    Ozawa, Tomoko
    Berger, Mitchel S.
    Aftab, Dana T.
    Prados, Michael D.
    Haas-Kogan, Daphne A.
    NEURO-ONCOLOGY, 2011, 13 (04) : 384 - 392
  • [39] MOLECULAR DETERMINANTS OF SENSITIVITY TO PI3K/AKT/mTOR PATHWAY INHIBITION IN GLIOBLASTOMA
    von Achenbach, Caroline
    Weller, Michael
    Kaulich, Kerstin
    Gramatzki, Dorothee
    Zacher, Angela
    Fabbro, Doriano
    Reifenberger, Guido
    Szabo, Emese
    NEURO-ONCOLOGY, 2018, 20 : 48 - 48
  • [40] Opposing influence of activin and TGFβ on PI3K and MEK/ERK signaling in colon cancer
    Bauer, Jessica I.
    Akagi, Naomi
    Ozden, Ozkan
    Principe, Daniel R.
    Carroll, Timothy
    Baik, Seung Hyun
    Spehlmann, Martina E.
    Eckmann, Lars
    Grippo, Paul J.
    Jung, Barbara
    CANCER RESEARCH, 2015, 75
12345